Historique
Article de Périodique
Extended-release subcutaneous buprenorphine. The 3rd therapeutic revolution (2024)
Auteur(s) :
REISINGER, M. ;
REISINGER, M.
Année
2024
Page(s) :
art. 42
Langue(s) :
Anglais
Refs biblio. :
21
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Thésaurus mots-clés
TRAITEMENT DE MAINTENANCE
;
BUPRENORPHINE
;
VOIE D'ADMINISTRATION
;
VOIE SOUSCUTANEE
;
OPIOIDES
;
HEROINE
;
DEPENDANCE
;
RECOMMANDATION
Autres mots-clés
Résumé :
Vincent Dole described the discovery of methadone treatment for heroin addicts in 1963 as a "therapeutic revolution". Twenty years later, buprenorphine constituted a second therapeutic revolution. Therapeutic safety and the absence of euphoria give patients a high degree of autonomy, making it possible to bypass the lobby of addiction specialists who were blocking any progress in opioid agonist treatments in France, a country where high-dose buprenorphine was first introduced worldwide. Forty years on, extended-release subcutaneous buprenorphine is emerging as a third therapeutic revolution. Monthly injections make it easier to stop taking the drug, thanks to the elimination of the behavioural reinforcement of daily intake. [Author's abstract]
Affiliation :
European Opiate Addiction Treatment Association, Bruxelles, Belgium